Reliability and validity of speech & pause measures during passage reading in ALS.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Carolina BarnettYana Yunusova

Abstract

Objective: The use of speech measures is becoming a common practice in the assessment of bulbar disease progression in amyotrophic lateral sclerosis (ALS). This study aimed to establish psychometric properties (e.g. reliability, validity, sensitivity, specificity) of speech and pause timing measures during a standardized passage. Methods: A large number of passage recordings (ALS N = 775; Neurotypical controls N = 323) was analyzed using a semi-automatic method (Speech and Pause Analysis, SPA). Results: The results revealed acceptable reliability of the speech and pause measures across repeated recording by the control participants. Strong construct validity was established via significant group differences between patients and controls and correlation statistics with clinical measures of overall ALS and bulbar disease severity. Speaking rate, pause events, and mean pause duration were able to detect ALS participants at the presymptomatic stage of bulbar disease with a good discrimination ability (AUC 0.81). Conclusions: Based on the current psychometric evaluation, performing passage recording and speech and pause timing analysis was deemed useful for detecting early and progressive changes associated with bulbar ALS.

References

Feb 1, 1996·Journal of Speech and Hearing Research·H L MitchellP J Watson
Jul 24, 2001·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·B R BrooksUNKNOWN World Federation of Neurology Research Group on Motor Neuron Diseases
Oct 26, 2001·Journal of the Neurological Sciences·L J BallG L Pattee
Dec 26, 2001·Journal of Clinical Epidemiology·D E BeatonJ G Wright
Apr 25, 2003·Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases·Martin HechtBernhard Neundörfer
Mar 3, 2009·Physical Therapy·Leslie G Portney
Sep 2, 2010·Behavior Research Methods·Yu-Tsai WangCara Ullman
Aug 1, 2013·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Jordan R GreenJames D Berry
Nov 18, 2015·Muscle & Nerve·Michael BenatarLucie Bruijn
Jan 11, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Richard SmithGary Pattee
Mar 31, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Kristen M AllisonJordan R Green
Apr 21, 2017·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Emily K PlowmanGary Pattee
Apr 26, 2017·Frontiers in Psychology·Jonathan Z Bakdash, Laura R Marusich
Nov 10, 2018·International Journal of Speech-language Pathology·Jun WangJordan R Green
Mar 7, 2019·Frontiers in Neurology·Yana YunusovaPeter Bede

❮ Previous
Next ❯

Citations

Dec 9, 2020·American Journal of Speech-language Pathology·Ashley A WaitoYana Yunusova
Jul 6, 2021·Frontiers in Neurology·Kaila L StipancicJordan R Green

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Related Papers

Critical Care Nurse
Jonathan B Bartels
Arizona Medicine
W B McGrath
U.S. News & World Report
Bernadine Healy
© 2021 Meta ULC. All rights reserved